Healthcare Value Capital, LLC
Follow13F filer, CIK 1458461, Woodcliff Lake, NJ
Healthcare Value Capital, LLC reported $33,971,000 across 16 holdings for the quarter ended 2019-12-31, in a 13F-HR filed 2020-02-14. Its ten largest share positions make up 90.25% of the portfolio.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000919574-20-001552
- Period
- 2019-12-31
- Reported value
- $34M
- Holdings
- 16
- Top 10 weight
- 90.25%
- New
- 2
- Sold out
- 8
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| ANTARES PHARMA INCadded | +100,000 | $470K |
| FOAMIX PHARMACEUTICALS LTDadded | +100,000 | $333K |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| WALGREENS BOOTS ALLIANCE INCexited | -50,000 | -$2.77M |
| CLOVIS ONCOLOGY INCreduced | -100,000 | -$1.04M |
| ADAMAS PHARMACEUTICALS INCexited | -200,000 | -$1.02M |
| NOVELION THERAPEUTICS INCexited | -1,400,000 | -$1.01M |
| GREENLANE HLDGS INCreduced | -25,000 | -$81.4K |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q4 2019
Share positions as resolved from 13F-HR 0000919574-20-001552, largest first. % of portfolio is the value over $32,003,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| GLAXOSMITHKLINE PLC-ADRGLAXOSMITHKLINE PLC-ADR | 100,000 | $4.7M | 14.68% | 0 | |||
| GILDGILEAD SCIENCES INC | 70,000 | $4.55M | 14.21% | 0 | Timeline | ||
| ABBVABBVIE INC | 50,000 | $4.43M | 13.83% | 0 | Timeline | ||
| CVSCVS HEALTH CORP | 50,000 | $3.71M | 11.61% | 0 | Timeline | ||
| TYME TECHNOLOGIES INC COMTYME TECHNOLOGIES INC COM | 2,175,000 | $3.04M | 9.51% | 0 | |||
| VKTXVIKING THERAPEUTICS INC | 250,000 | $2M | 6.27% | 0 | Timeline | ||
| CAHCARDINAL HEALTH INC | 35,000 | $1.77M | 5.53% | 0 | Timeline | ||
| CORCENCORA INC | 20,000 | $1.7M | 5.31% | 0 | Timeline | ||
| CLOVIS ONCOLOGY INCCLOVIS ONCOLOGY INC | 150,000 | $1.56M | 4.89% | -100,000 | |||
| ANTARES PHARMA INCANTARES PHARMA INC | 300,000 | $1.41M | 4.41% | +100,000 | |||
| MCKMCKESSON CORP | 10,000 | $1.38M | 4.32% | 0 | Timeline | ||
| FOAMIX PHARMACEUTICALS LTDFOAMIX PHARMACEUTICALS LTD | 350,000 | $1.17M | 3.64% | +100,000 | |||
| GREENLANE HLDGS INCGREENLANE HLDGS INC | 175,000 | $570K | 1.78% | -25,000 |
Options
Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).
| Security | Type | Amount | Value | Change |
|---|---|---|---|---|
| CLOVIS ONCOLOGY INCCLOVIS ONCOLOGY INC COM | call | 100,000 | $1.04M | new |
| ADAMAS PHARMACEUTICALS INCADAMAS PHARMACEUTICALS INC COM | call | 200,000 | $758K | new |
| FOAMIX PHARMACEUTICALS LTDFOAMIX PHARMACEUTICALS LTD SHS | call | 50,000 | $167K | 0 |
Sold out in Q4 2019
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| SPYSTATE STR SPDR S&P 500 ETF T | 50,000 | $14.8M | put |
| Proshares VIX Short-TermProshares VIX Short-Term | 200,000 | $3.9M | call |
| GILDGILEAD SCIENCES INC | 50,000 | $3.17M | call |
| WALGREENS BOOTS ALLIANCE INCWALGREENS BOOTS ALLIANCE INC | 50,000 | $2.77M | shares |
| ADAMAS PHARMACEUTICALS INCADAMAS PHARMACEUTICALS INC | 200,000 | $1.02M | shares |
| NOVELION THERAPEUTICS INCNOVELION THERAPEUTICS INC | 1,400,000 | $1.01M | shares |
| ANTARES PHARMA INCANTARES PHARMA INC | 200,000 | $669K | call |
| TYME TECHNOLOGIES INC COMTYME TECHNOLOGIES INC COM | 100,000 | $119K | call |
How Q4 2019 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000919574-20-001552 | base | 2020-02-14 | acceptance time not in the bulk data set |